Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Key facts

Sponsor

National Cancer Institute (NCI)

Principal Investigator

Adam S Levy

Children's Oncology Group

Intervention

Bevacizumab(biological)

Enrollment

108 enrolled

Eligibility

21 years · All sexes

Timeline

2010 – 2021

Study locations (30)

• Children's Hospital of Alabama, Birmingham, Alabama, United States
• University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
• Phoenix Childrens Hospital, Phoenix, Arizona, United States
• Arkansas Children's Hospital, Little Rock, Arkansas, United States
• University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
• Kaiser Permanente Downey Medical Center, Downey, California, United States
• Loma Linda University Medical Center, Loma Linda, California, United States
• Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
• Children's Hospital Los Angeles, Los Angeles, California, United States
• Cedars Sinai Medical Center, Los Angeles, California, United States
• Valley Children's Hospital, Madera, California, United States
• Kaiser Permanente-Oakland, Oakland, California, United States
• Children's Hospital of Orange County, Orange, California, United States
• Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
• Sutter Medical Center Sacramento, Sacramento, California, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.